Food delivery partnerships and pharmaceutical partnerships (GLP-1 co-marketing agreements with manufacturers) are now embedded in some premium tiers
WeightWatchers: companion programme for GLP-1 users In the UK, WeightWatchers GLP-1 programme is a companion service, not a prescriber
The new WeightWatchers GLP-1 Program, which was developed by WeightWatchers team of obesity specialists, clinicians, behavior-change scientists, dietitians and fitness experts, solves a gap in the market as members navigate life on new weight loss medications
Nausea, vomiting, constipation, and diarrhea occur in 1040% of users, typically resolving within 48 weeks
Clinical trials show average weight loss of 15-22% of baseline body weight over 52-68 weekssubstantially greater than behavioral interventions alone
In addition to helping diabetics with insulin resistance issues, each of these injectables gained popularity in recent years because of their ability to facilitate weight loss